cetuximab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mucinous Gastrointestinal Adenocarcinoma
Conditions
Mucinous Gastrointestinal Adenocarcinoma
Trial Timeline
Nov 1, 2004 → Jan 1, 2007
NCT ID
NCT00162110About cetuximab
cetuximab is a phase 2 stage product being developed by Eli Lilly for Mucinous Gastrointestinal Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00162110. Target conditions include Mucinous Gastrointestinal Adenocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00698841 | Phase 2 | Completed |
| NCT00292955 | Phase 2 | UNKNOWN |
| NCT00362102 | Phase 2 | Completed |
| NCT00207116 | Phase 1 | Completed |
| NCT00082212 | Phase 2 | Terminated |
| NCT00162110 | Phase 2 | Completed |
| NCT00083720 | Phase 2 | Completed |
| NCT00207155 | Phase 1 | Completed |
| NCT00063388 | Phase 2 | Completed |
| NCT00055419 | Phase 2 | Completed |
Competing Products
2 competing products in Mucinous Gastrointestinal Adenocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| panitumumab + irinotecan hydrochloride + fluorouracil + leucovorin calcium | Amgen | Phase 2 | 51 |
| aflibercept + oxaliplatin + leucovorin + fluorouracil | Sanofi | Phase 2 | 51 |